口蹄疫(Foot and mouth disease, FMD)為高度傳染性之病毒性疾病，造成偶蹄類動物之水疱性疾病，對農畜業經濟影響重大。口蹄疫病毒是屬於小核醣核酸病毒科中的口瘡病毒屬，共有七個血清型，而台灣地區流行的病毒株以O型為主。口蹄疫病毒由VP1,VP2,VP3,VP4 四個結構蛋白組成，其中 VP1具有最多抗原決定位，可以誘導專一性免疫反應。
本研究的目的是以重組FMDV之結構蛋白基因裝載入pET24a載體以大腸桿菌表現系統表現此重組蛋白，將蛋白質純化後，再利用市售抗His抗體及抗FMDV VP1多株抗體進行西方點墨法和ELISA，以確認重組蛋白抗原性。
以重組VP1蛋白與ISA206佐劑混合製成次單位疫苗免疫小鼠，經由抗體力價試驗，確定疫苗對於小鼠會產生效力。未來期望可以在豬隻身上進行更多的測試，以證明重組VP1蛋白可具有良好保護效力。

Foot and mouth disease (FMD) is a highly contagious viral disease of cloven-hoofed animals, and causing very huge economic losses. The infection of the virus induces vesicular. FMDV belongs to genus Aphthovirus within the family Piconaviridae. There are seven serotypes of FMDV. The O type virus is the main strain in Taiwan. There are VP1-VP4 which are the four structural proteins of FMDV. The VP1 carries important epitopes against FMDV inducing specific immune responses.
The goal of this study was to recombinant FMDV VP1 gene into the pET24a vector, and used the Escherichia coli expression system to express this recombinant protein. After purified, the protein antigenicity was characterized by western blot and ELISA with anti-His and anti-FMDV VP1 to confirm the antigenic of recombinant protein.
The VP1 protein was mixed with ISA206 adjuvant to produce subunit vaccine. The efficacy of recombinant protein vaccine was determined by antibody titer test. The results showed that the group of vaccine antibody titer higher than negative control. The immne result proved that the recombinant protein had immunogenic for FMDV, which suggest that the subunit vaccne may be a valuable vaccine candidate to prevent FMD on swine.

摘 要 I
Abstract II
謝誌 ………………………………………………………………………….IV
目錄 …………………………………………………………………………..V
圖表目錄 VII
第1章 緒言 1
第2章 文獻回顧 3
2.3口蹄疫病毒分類與病理特性 (Foot-and-mouth disease virus, FMDV) 4
2.4 口蹄疫病毒基因組成 5
2.5 口蹄疫疫苗簡介 6
2.6 疫苗對口蹄疫疫情控制 7
第3章 材料與方法 13
3.1口蹄疫病毒基因片段來源 13
3.1.1口蹄疫O/TWN/99之P12A基因片段 13
3.1.2 pUC57-P12A 質體抽取 13
3.2.1 設計O99-VP1引子基因序列(Table 1) 13
3.2.2 聚合酶連鎖反應 (Polymerase chain reaction, PCR) 14
3.2.3膠體電泳法確認PCR產物大小 14
3.2.4 O99-VP1基因片段純化 14
3.3.1 限制酶酵素切割 (Enzyme digestion) 15
3.3.3 pET24a-O99-VP1轉型至勝任細胞DH5α (Transformation) 15
3.3.4 確認pET24a-O99-VP1基因 15
3.3.5 抽取pET24a-O99-VP1質體 16
3.5.4純化重組O99-VP1蛋白 19
3.5.5重組O99-VP1蛋白透析 19
3.5.6重組O99-VP1蛋白定量 20
3.6 疫苗製作 20
3.7 動物試驗 20
3.7.1 小鼠免疫 20
3.7.2 檢測小鼠血清Total IgG 21
3.7.3 檢測小鼠血清IgG1 21
3.7.4 檢測小鼠血清 IgG2a 22
3.7.5 小鼠脾臟細胞製備 23
3.7.6 淋巴細胞之計數 23
3.7.6 小鼠淋巴細胞增殖反應 24
3.7.7 計算細胞增生刺激指數 (Stimulation index, SI) 24
3.7.8 萃取小鼠脾臟細胞RNA 24
3.7.9 反轉錄聚合酶連鎖反應 (Reverse transcription PCR, RT-PCR) 25
3.7.10 即時聚合酶連鎖反應 (Real-time Quantitative PCR, Q-PCR) 25
第4章 結果 26
4.1 pET24a-O99-VP1之質體建構 26
4.2 大腸桿菌表現pET24a-O99-VP1蛋白之條件及抗原分析 26
4.3重組O99-VP1蛋白純化 26
4.4 重組O99-VP1蛋白透析 27
4.5 第一次動物實驗免疫後小鼠血液中的Total IgG抗體分析 27
4.6 第一次ICR小鼠試驗結果分析: IgG1 and IgG2a 28
4.7 第二次動物實驗免疫後小鼠血液中的Total IgG抗體分析 28
4.8 第二次BALB/c小鼠試驗結果分析: IgG1 and IgG2a 29
4.9 第二次BALB/c小鼠試驗結果分析:細胞激素( Cytokine) 29
第6章 參考文獻 51
作者簡介 59

1. 梁文榮, 陳聰周. 查獲走失動物或動物產品之檢疫處理. 動植物防疫檢疫季刊. 2007; 14:36-38.
2. 鄭秀蓮. 陸生動物衛生法典之口蹄疫封鎖區規定. 動植物防疫檢疫季刊. 2008; 16:49-51.
3. 陳惠玫. 國際重要動物疫情. 動植物防疫檢疫季刊. 2017; 51:46-51.
4. 鄭益謙. 我國撲滅豬瘟及口蹄疫的重要性. 撲滅豬瘟及口蹄疫防疫宣傳手冊. 2009.
5. 朱瑞民, 楊平政, 鄭益謙. 綜說: 口蹄疫. 中華獸醫誌. 1997; 23(6):477-491.
6. Alibolandi M, Mirzahoseini H. Chemical assistance in refolding of bacterial inclusion bodies. Biochemistry research international. 2011;2011:631607.
7. Bahnemann HG. Inactivation of viruses in serum with binary ethyleneimine. Journal of clinical microbiology. 1976;3:209-10.
8. Barnett PV, Cox SJ, Aggarwal N, Gerber H, McCullough KC. Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine. Vaccine. 2002;20:3197-208.
9. Barteling SJ, Vreeswijk J. Developments in foot-and-mouth disease vaccines. Vaccine. 1991;9:75-88.
10. Belsham GJ. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Progress in Biophysics and Molecular Biology. 1993;60:241-60.
11. Belsham GJ. Translation and replication of FMDV RNA. Current topics in microbiology and immunology. 2005;288:43-70.
12. Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature. 1982;298:30-3.
13. Borrego B, Camarero JA, Mateu MG, Domingo E. A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Viral immunology. 1995;8:11-8.
14. Brown F. The history of research in foot-and-mouth disease. Virus Research. 2003;91:3-7.
15. Cedillo-Barron L, Foster-Cuevas M, Cook A, Gutiérrez-Castañeda B, Kollnberger S, Lèfevre F, et al. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine. Vaccine. 2003;21:4261-9.
16. Chan EWC, Wong HT, Cheng SCS, Yan WY, Zheng ZX, Sheng ZT, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine. Vaccine. 2000;19:538-46.
17. Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. Journal of virology. 1998;72:4454-7.
18. Chinsangaram J, Mason PW, Grubman MJ. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine. 1998;16:1516-22.
19. Cleland PC, Chamnanpood P, Baldock FC, Gleeson LJ. Questionnaire survey of foot and mouth disease (FMD) and of FMD control by vaccination in villages in northern Thailand. Revue scientifique et technique (International Office of Epizootics). 1995;14:567-75.
20. Cook A, Angove H, Cedillo-Barron L, Foster-Cuevas M, Parkhouse RM. Cellular and humoral immunity to foot-and-mouth disease virus and its non-structural proteins in infected swine. Biochemical Society transactions. 1997;25:273s.
21. Cottam EM, Wadsworth J, Shaw AE, Rowlands RJ, Goatley L, Maan S, et al. Transmission pathways of foot-and-mouth disease virus in the United Kingdom in 2007. PLoS pathogens. 2008;4:e1000050.
22. Cox SJ, Barnett PV, Dani P, Salt JS. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 1999;17:1858-68.
23. Cubillos C, de la Torre BG, Jakab A, Clementi G, Borras E, Barcena J, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. Journal of virology. 2008;82:7223-30.
24. Diaz-San Segundo F, Medina GN, Ramirez-Medina E, Velazquez-Salinas L, Koster M, Grubman MJ, et al. Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response. Journal of virology. 2015;90:1298-310.
25. Diaz-San Segundo F, Medina GN, Stenfeldt C, Arzt J, de los Santos T. Foot-and-mouth disease vaccines. Veterinary Microbiology.
26. Doel TR. Optimisation of the immune response to foot-and-mouth disease vaccines. Vaccine. 1999;17:1767-71.
27. Doel TR. FMD vaccines. Virus Research. 2003;91:81-99.
28. Doel TR, Williams L, Barnett PV. Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine. 1994;12:592-600.
29. Domingo E, Baranowski E, Escarmis C, Sobrino F. Foot-and-mouth disease virus. Comparative immunology, microbiology and infectious diseases. 2002;25:297-308.
30. Donaldson AI. Foot-and-mouth disease in Taiwan. The Veterinary record. 1997;140:407.
31. Donaldson AI, Kihm U. Research and technological developments required for more rapid control and eradication of foot and mouth disease. Revue scientifique et technique (International Office of Epizootics). 1996;15:863-73.
32. Fowler VL, Bashiruddin JB, Maree FF, Mutowembwa P, Bankowski B, Gibson D, et al. Foot-and-mouth disease marker vaccine: Cattle protection with a partial VP1 G–H loop deleted virus antigen. Vaccine. 2011;29:8405-11.
33. Freiberg B, Rahman MM, Marquardt O. Genetical and immunological analysis of recent Asian type A and O foot-and-mouth disease virus isolates. Virus genes. 1999;19:167-82.
34. Grubman MJ, Baxt B. Foot-and-mouth disease. Clinical microbiology reviews. 2004;17:465-93.
35. Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Veterinary research. 2013;44:48.
36. Huang CC, Jong MH, Lin SY. Characteristics of foot and mouth disease virus in Taiwan. The Journal of veterinary medical science. 2000;62:677-9.
37. Huang C-C, Lin Y-L, Huang T-S, Tu W-J, Lee S-H, Jong M-H, et al. Molecular characterization of foot-and-mouth disease virus isolated from ruminants in Taiwan in 1999–2000. Veterinary Microbiology. 2001;81:193-205.
38. Huang H, Yang Z, Xu Q, Sheng Z, Xie Y, Yan W, et al. Recombinant fusion protein and DNA vaccines against foot and mouth disease virus infection in guinea pig and swine. Viral immunology. 1999;12:1-8.
39. Iyer AV, Ghosh S, Singh SN, Deshmukh RA. Evaluation of three ‘ready to formulate’ oil adjuvants for foot-and-mouth disease vaccine production. Vaccine. 2000;19:1097-105.
40. Jackson T, Mould AP, Sheppard D, King AM. Integrin alphavbeta1 is a receptor for foot-and-mouth disease virus. Journal of virology. 2002;76:935-41.
41. Kesy A. Global situation of foot-and-mouth disease (FMD)--a short review. Polish journal of veterinary sciences. 2002;5:283-7.
42. Kitching RP. The application of biotechnology to the control of foot-and-mouth disease virus. The British veterinary journal. 1992;148:375-88.
43. Kitching RP. A recent history of foot-and-mouth disease. Journal of comparative pathology. 1998;118:89-108.
44. Kleid DG, Yansura D, Small B, Dowbenko D, Moore DM, Grubman MJ, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (New York, NY). 1981;214:1125-9.
45. Lee SH, Jong MH, Huang TS, Lin YL, Wong ML, Liu CI, et al. Pathology and viral distributions of the porcinophilic foot-and-mouth disease virus strain (O/Taiwan/97) in experimentally infected pigs. Transboundary and emerging diseases. 2009;56:189-201.
46. Li Z, Yi Y, Yin X, Zhang Y, Liu M, Liu H, et al. Development of a foot-and-mouth disease virus serotype A empty capsid subunit vaccine using silkworm (Bombyx mori) pupae. PloS one. 2012;7:e43849.
47. Lombard M, Fussel AE. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination. Revue scientifique et technique (International Office of Epizootics). 2007;26:117-34.
48. Lubroth J, Grubman MJ, Burrage TG, Newman JFE, Brown F. Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals. Vaccine. 1996;14:419-27.
49. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine. 2001;19:2152-62.
50. McCullough KC, De Simone F, Brocchi E, Capucci L, Crowther JR, Kihm U. Protective immune response against foot-and-mouth disease. Journal of virology. 1992;66:1835-40.
51. Miller LC, Blakemore W, Sheppard D, Atakilit A, King AM, Jackson T. Role of the cytoplasmic domain of the beta-subunit of integrin alpha(v)beta6 in infection by foot-and-mouth disease virus. Journal of virology. 2001;75:4158-64.
52. Murphy FA. The threat posed by the global emergence of livestock, food-borne, and zoonotic pathogens. Annals of the New York Academy of Sciences. 1999;894:20-7.
53. Nunez JI, Baranowski E, Molina N, Ruiz-Jarabo CM, Sanchez C, Domingo E, et al. A single amino acid substitution in nonstructural protein 3A can mediate adaptation of foot-and-mouth disease virus to the guinea pig. Journal of virology. 2001;75:3977-83.
54. Porter AG. Picornavirus nonstructural proteins: emerging roles in virus replication and inhibition of host cell functions. Journal of virology. 1993;67:6917-21.
55. Robiolo B, Grigera PR, Periolo OH, Seki C, Bianchi T, Maradei E, et al. Assessment of foot and mouth disease vaccine potency by liquid-phase blocking ELISA: a proposal for an alternative to the challenge procedure in Argentina. Vaccine. 1995;13:1346-52.
56. Rodriguez A, Sáiz JC, Novella IS, Andreu D, Sobrino F. Antigenic Specificity of Porcine T Cell Response against Foot-and-Mouth Disease Virus Structural Proteins: Identification of T Helper Epitopes in VP1. Virology. 1994;205:24-33.
57. Rodriguez LL, Grubman MJ. Foot and mouth disease virus vaccines. Vaccine. 2009;27, Supplement 4:D90-D4.
58. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in microbiology. 2014;5:172.
59. Rueckert RR, Wimmer E. Systematic nomenclature of picornavirus proteins. Journal of virology. 1984;50:957-9.
60. Sáiz M, Núñez JI, Jimenez-Clavero MA, Baranowski E, Sobrino F. Foot-and-mouth disease virus: biology and prospects for disease control. Microbes and Infection. 2002;4:1183-92.
61. Salt JS. The carrier state in foot and mouth disease--an immunological review. The British veterinary journal. 1993;149:207-23.
62. Salt JS, Barnett PV, Dani P, Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 1998;16:746-54.
63. Samuel AR, Knowles NJ. Foot-and-mouth disease virus: cause of the recent crisis for the UK livestock industry. Trends in genetics : TIG. 2001;17:421-4.
64. Thomson GR, Vosloo W, Bastos ADS. Foot and mouth disease in wildlife. Virus Research. 2003;91:145-61.
65. Uddowla S, Hollister J, Pacheco JM, Rodriguez LL, Rieder E. A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals. Journal of virology. 2012;86:11675-85.
66. Weber S, Granzow H, Weiland F, Marquardt O. Intracellular membrane proliferation in E. coli induced by foot-and-mouth disease virus 3A gene products. Virus genes. 1996;12:5-14.
67. Wong HT, Cheng SC, Chan EW, Sheng ZT, Yan WY, Zheng ZX, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology. 2000;278:27-35.
68. Wu Q, Moraes MP, Grubman MJ. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine. Virus Research. 2003;93:211-9.
69. Xia Y, Park Y-D, Mu H, Zhou H-M, Wang X-Y, Meng F-G. The protective effects of osmolytes on arginine kinase unfolding and aggregation. International Journal of Biological Macromolecules. 2007;40:437-43.
70. Zheng M, Jin N, Zhang H, Jin M, Lu H, Ma M, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. Journal of Virological Methods. 2006;136:230-7.
71. Zhou CX, Li D, Chen YL, Lu ZJ, Sun P, Cao YM, et al. Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine. BMC veterinary research. 2014;10:2.